AzTrials
AzTrials

EncephalitisSEAeNCT04089436

SouthEast Asia Encephalitis Project

An observational study of Encephalitis, run by Institut Pasteur at 7 sites in 4 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Encephalitis, an acute inflammation of the central nervous system associated with neurologic dysfunction is of public health concern worldwide, because of its high mortality and neurological sequelae rates. In Asia where many of the possible etiologies are of major public health concerns (i.e. Read more about this study

Who is it for?
Ages 28 days and older
Conditions the study is for
Encephalitis
What is being tested?
CSF sampling, Blood sampling and Nasopharyngeal and rectal sampling
Type of treatment
Injection or infusion
How many people
800 participants
Where
7 sitesin 4 countries
Study dates
15 Jul 2014to 31 Dec 2019
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 28 days and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar.

Who may be able to join

  • presenting altered mental status (i.e. confusion or inability to talk, decreased or altered level of consciousness or personality change AND lasting 24 hours or more AND no alternative cause identified);
  • AND at least one of minor inclusion criteria must be met before patient inclusion:
  • presenting fever (38°C axillary) for less than 72 hours before or after presentation;
  • seizure (febrile seizure excluded);
  • focal neurologic finding.

Who cannot join

  • None

Trial locations and contacts

7 sites in 4 countries.

7 sites in 4 countries

Burma2 sites
  • National Health Laboratory

    Yangon

  • Yangon children hospital

    Yangon

Other trials in Burma

Cambodia2 sites
  • Institut Pasteur of Cambodia

    Phnom Penh

  • Kantha Bopha IV children Hospital

    Phnom Penh

Other trials in Cambodia

Vietnam2 sites
  • National Hospital of Pediatrics

    Hanoi

  • National Institute of Hygiene Epidemiology

    Hanoi

Other trials in Vietnam

Laos1 site
  • Mahidol Oxford Tropical Medicine Research Unit

    Vientiane

Other trials in Laos

About this study

Official title: The Threat of Infectious Encephalitis in Southeast Asia: SouthEast Asia Encephalitis Project

Encephalitis, an acute inflammation of the central nervous system associated with neurologic dysfunction is of public health concern worldwide, because of its high mortality and neurological sequelae rates. In Asia where many of the possible etiologies are of major public health concerns (i.e. dengue, Japanese encephalitis, West Nile virus, EV71), acute encephalitis is among the most frequent and severe causes of pediatric hospitalization.

Despite extensive microbiological investigations, no pathogen is identified for a significant proportion of encephalitis patients in both industrialized and developing countries (28-85% of cases remain unconfirmed). Unknown and sometimes new emerging infectious agents may be responsible for cases of currently unknown etiology and an intensive effort to identify and characterize them is to be done. From this perspective, the Southeast Asian region, a particularly significant biodiversity hotspot, is at high risk for new pathogen emergence.

Read more

Surveillance and diagnostic capabilities for encephalitis remain poor and still suffer from serious shortcomings in most Southeast Asian countries and beyond. Although the burden of non-infectious encephalitis in this region remains to be ascertained, the best laboratories only identify etiological infective agents in less than half of patients. Systematic data regarding the contribution of these diseases are lacking and to define the burden of these infections, to describe the full clinical spectrum and characteristics of acute central nervous system infections, and to develop diagnostic and therapeutic algorithms to improve patient care.

The proposed project is an ambitious and multidisciplinary research consortium that aims to reduce the morbidity and mortality associated with infectious encephalitis in Southeast Asia (Cambodia, Laos, Vietnam and Myanmar) by improving diagnosis and medical care for patients.

The SEAe project specific objectives are:

  • To fill-in the biomedical knowledge gaps regarding acute encephalitis syndrome;
  • To strengthen hospital laboratories capacities to enhance health by improving diagnosis and care for patients;
  • To identify unknown pathogens responsible for encephalitis;
  • To provide reliable information and a sustainable regional and sub-regional surveillance network to clinicians and public health stakeholders that will help them to better define prevention policies, vaccination strategy, and build preparedness to emerging infectious risks.
Read the detailed description

Background:

Encephalitis is defined as an acute inflammation of the central nervous system associated with neurologic dysfunction. The most common etiologies are infections by either viruses or bacteria although parasites and fungi can also be occasionally detected, especially in immunocompromised patients. Because of high mortality and long-term neurological sequelae, encephalitis is of public health concern worldwide. Reported incidences range between 3.5 and 7.4 cases per 100,000 patient-years with higher incidences in children than adults. Various encephalitis outbreaks have recently emerged in Asia such as the fatal outbreak of enterovirus 71 (EV71) that occurred in mid-2012 in Cambodia affecting very young children (most below 3 years, all below 12 years). In Asia where many of the possible etiologies are of major public health concerns (i.e. dengue, Japanese encephalitis, West Nile virus, EV71), acute encephalitis is among the most frequent and severe causes of pediatric hospitalization.

Despite extensive microbiological investigations and the use of the most advanced molecular biology-based assays, no pathogen is identified for a significant proportion of encephalitis patients in both industrialized and developing countries (28-85% of cases remain unconfirmed). Previous studies support the hypothesis that unknown and sometimes new emerging infectious agents may be responsible for cases of currently unknown etiology and strongly argue for an intensive effort to identify and characterize them. This hypothesis is also strengthened by the recent apparent increase in emerging infectious diseases, many of which have been linked to human activities that impact the environment and to the spreading of pathogens to new geographic regions. From this perspective, the Southeast Asian region, a particularly significant biodiversity hotspot, is at high risk for new pathogen emergence. Indeed, growing human populations, increasing urbanization and frequent contact with wildlife and domesticated animals have created novel opportunities for the emergence of pathogens such as SARS at the end of 2002, and highly facilitated the spread of infectious diseases such as H5N1 high-pathogenicity avian influenza virus since 2004, and H1N1 pandemic influenza virus in 2009. The population in developing Southeast Asian countries is particularly at risk for the circulation of emerging or reemerging infectious agents and for this reason the surveillance and investigation of acute encephalitis syndrome in this region is of utmost public health importance, both locally and globally.

Surveillance and diagnostic capabilities for encephalitis remain poor and still suffer from serious shortcomings in most Southeast Asian countries and beyond. Although the burden of non-infectious encephalitis in this region remains to be ascertained, the best laboratories only identify etiological infective agents in less than half of patients. Moreover, because of the absence of reliable microbiological diagnostic capacity in the majority of public referral hospitals, local clinicians have to treat acute encephalitis syndromes mostly empirically, with little evaluation of the effectiveness of their clinical approach. Even if some of the most common causes of acute encephalitis syndrome may be vaccine-preventable, systematic data regarding the contribution of these diseases are lacking and no reliable data are available to define the burden of these infections, to describe the full clinical spectrum and characteristics of acute central nervous system infections, and to develop diagnostic and therapeutic algorithms to improve patient care. Besides, whatever the nature and magnitude of the encephalitis burden in Southeast Asia and the criteria used to assess it (i.e. morbidity, mortality, handicap, impact on families' budget or livelihood), this burden is borne principally by underprivileged populations with limited access to prevention and health care.

Project partners The proposed project is an ambitious and multidisciplinary research consortium associating: (i) national health authorities in Cambodia, Lao PDR, Vietnam and Myanmar; (ii) local major university and clinical sites (national hospitals and provincial health centers); (iii) key French stakeholders of life and health sciences with research activities carried out in the Southeast Asian region such as: Institut Pasteur and the Institut Pasteur International Network, Institut National de la Santé et de la Recherche Médicale (Inserm), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad), Institut de Recherche pour le Développement (IRD) - Aix-Marseille University - Ecole des Hautes Etudes en Santé Publique (EHESP); and (iv) teams from the Southeast Asian Wellcome Trust Oxford University Major Overseas Programme.

Objectives:

The SEAe project aims to reduce the morbidity and mortality associated with infectious encephalitis in Southeast Asia by improving diagnosis and medical care for patients.

The SEAe project specific objectives are:

  • To fill-in the biomedical knowledge gaps regarding acute encephalitis syndrome;
  • To strengthen hospital laboratories capacities to enhance health by improving diagnosis and care for patients;
  • To identify unknown pathogens responsible for encephalitis;
  • To document and analyze factors related to clusters of encephalitis cases integrating human health, animal health and environment through a "One Health" approach;
  • To provide reliable information and a sustainable regional and sub-regional surveillance network to clinicians and public health stakeholders that will help them to better define prevention policies, vaccination strategy, and build preparedness to emerging infectious risks.

Population study: patient with suspected encephalitis hospitalized in in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, Yangon Children Hospital, Yangon, Myanmar. Inclusion criteria were adapted from the International Encephalitis Consortium 2013: all patients should be older than 28 days and presenting an altered mental status (i.e. confusion or inability to talk, decreased or altered level of consciousness or personality change) lasting more than 24 hours without alternative cause identified. These criteria should be associated with at least one of the following: (i) fever (>=38°C axillary) for less than 72 hours before or after presentation; (ii) seizure (febrile seizure excluded); (iii) focal neurologic finding.

Data collection:

Clinical data entries are required for this study.

Data entries:

A single data entry person (a medical doctor) enters clinical information and fill in a paper form at admission, at 24 hours, at discharge and one year after discharge and enter the data into an OpenClinica (hosted in CIRAD server, Montpellier, France ) anonymized online database.

Laboratory data is entered into a customized ACCESS (Microsoft database). The results are entered into dedicated tabs for the different techniques.

A data manager dedicated to the study is in charge of the database. The CIRAD and the Institut Pasteur share the co-ownership of the database.

First statistical analysis will be performed in Institut Pasteur du Cambodge, Phnom Penh, under epidemiology unit responsibility. Continuous data will be described with descriptive statistics, including mean ±SD and/or median (range) as appropriate and categorical data with frequencies (%). Categorical data will be analyzed by univariate analysis with χ2 or Fisher exact test as appropriate and continuous data by nonparametric Mann-Whitney test. Statistical analyses will involve use of R software. Relationships between clinical, biological, radiological variables, etiologies and outcome will be assessed by using a univariate and multivariate logistic regression analyses to identify determinants for poor outcome.

Study Calendar

  • Provisional inclusion starting date: July 2014
  • Provisional inclusion duration: 3 years and half
  • Patient participation duration: 1 year
  • Study provisional duration: 5 years
  • Data archiving duration: 15 years
Conditions
Encephalitis
Being tested
CSF sampling, Blood sampling, Nasopharyngeal and rectal sampling
Keywords
Encephalitis, Southeast Asia, Japanese encephalitis, Next Generation sequencing
Medical subject headings
Encephalitis, Encephalitis, Japanese

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CSF samplingDiagnostic test

    CSF sampling by lumbar puncture

  • Blood samplingDiagnostic test

    Blood sampling by blood test

  • Nasopharyngeal and rectal samplingDiagnostic test

    Nasopharyngeal and rectal sample by swabbing

Study groups in NCT04089436
Study groupRoleWhat they receive
patients with encephalitischildren above 28days and adults with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar
Receives: Diagnostic Test: CSF sampling; Diagnostic Test: Blood sampling; Diagnostic Test: Nasopharyngeal and rectal sampling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Identify etiologies of encephalitis in South East Asia (Vietnam, Laos, Cambodia and Myanmar).

    Proportion of patients with confirmed or probable etiologies and proportion with unidentified pathogen

    Measured: August 2019

Secondary outcomes (3)
  1. Describe clinical and biological features of patients with encephalitis

    Proportion of participants by demographic data (geographic origin, age), by clinical and biological features assessed by physician (general symptoms, neurological symptoms, length of symptoms, blood pressure, blood pulse, weight, height, white blood cells, platelets counts, hemoglobin, CSF cells, protein glucose levels).

    Measured: August 2019

  2. describe clinical outcomes of encephalitis in general and by etiology

    Proportion of patient who died or had neurological sequelae or recovered during hospitalization and at one year

    Measured: December 2019

  3. Identify factors associated with death or severe neurological sequelea in patients with confirmed infectious encephalitis (survival analyses, sequelea score).

    Estimation of risk ratio for death or severe neurological sequelae in patients with confirmed infectious encephalitis by demographic, clinical, and biological data

    Measured: December 2019

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Sep 2019
  2. Study start15 Jul 2014
  3. Primary completion30 Sep 2019 (estimated)
  4. Study completion31 Dec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
800 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT04089436
Sponsor's protocol ID
2013-024
Acronym
SEAe
Status last verified
Sep 2019
First submitted
28 Jun 2019
Last updated
25 Sep 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Pommier JD, Gorman C, Crabol Y, Bleakley K, Sothy H, Santy K, Tran HTT, Nguyen LV, Bunnakea E, Hlaing CS, Aye AMM, Cappelle J, Herrant M, Piola P, Rosset B, Chevalier V, Tarantola A, Channa M, Honnorat J, Pinto AL, Rattanavong S, Vongsouvath M, Mayxay M, Phangmanixay S, Phongsavath K, Tin OS, Kyaw LL, Tin HH, Linn K, Tran TMH, Perot P, Thuy NTT, Hien N, Phan PH, Buchy P, Dussart P, Laurent D, Eloit M, Dubot-Peres A, Lortholary O, de Lamballerie X, Newton PN, Lecuit M; SEAe Consortium. Childhood encephalitis in the Greater Mekong region (the SouthEast Asia Encephalitis Project): a multicentre prospective study. Lancet Glob Health. 2022 Jul;10(7):e989-e1002. doi: 10.1016/S2214-109X(22)00174-7.

    PubMed 35714649

Questions about this trial

What is this clinical trial studying?

An observational study of Encephalitis, run by Institut Pasteur at 7 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in Burma, Cambodia, Vietnam, Laos. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Identify etiologies of encephalitis in South East Asia (Vietnam, Laos, Cambodia and Myanmar). (time frame: August 2019). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04089436, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in